Werewolf Therapeutics, Inc.
Developing tumor-activated immunotherapies for a localized immune attack on cancer.
HOWL | US
Overview
Corporate Details
- ISIN(s):
- US95075A1079
- LEI:
- Country:
- United States of America
- Address:
- 200 TALCOTT AVENUE, 2472 WATERTOWN
- Website:
- https://werewolftx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company's approach addresses the limitations of conventional immunotherapy, such as off-target side effects, by utilizing its proprietary PREDATOR™ protein engineering platform. This technology is used to create conditionally activated proinflammatory immune modulators, called INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become fully active only within the tumor microenvironment. This targeted mechanism aims to unleash a potent, localized immune attack on cancer cells while minimizing damage to healthy tissue.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Automate Your Workflow. Get a real-time feed of all Werewolf Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Werewolf Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Werewolf Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
